RxDoctor Payments Data

Mohammed Mahkri, MD

Gastroenterology · Aurora, ILNPI 1659351278

Payments from drug & device makers

$883in general payments, 2019–2025

Across 38 payments — averaging $23.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$276
  • Phathom Pharmaceuticals, Inc.$142
  • Bristol Myers Squibb$140
  • Sanofi$137
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$58
  • Aimmune Therapeutics, Inc.$43
  • plus $87 from 5 others

What the payments were for

  • Food & beverage$86798%
  • Education$162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$883 in reported general payments places this provider in the 40th percentile of 787 gastroenterology providers in Illinois.

See all gastroenterology providers in Illinois

Medicare billing

Part B allowed, 2024
$93,048
Medicare patients
352
Services billed
739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide64$45,943
TrulancePlecanatide11$6,150
Mesalamine12$4,323
Pantoprazole Sodium195$2,482
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates33$2,198
Omeprazole156$1,859
Sucralfate52$1,752
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl103$1,351
Azathioprine12$487
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl29$405
Famotidine25$345
Lactulose29$257
Lansoprazole12$115
Amitriptyline Hcl12$97
Spironolactone11$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$276$45,94364 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$58$6,15011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 787 gastroenterology providers in Illinois.

Other gastroenterology in Aurora

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →